News + Filings Transactions
|
RIGGS RORY B
Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
09/30/2023 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 345 | $52.09 | $18k | | 09/30/2023 |
08/08/2023 | Royalty Pharma plc | RPRX | Gift | LP interests in RPI US Partners 2019, LP | 6.5k | $0.00 | $0 | | 08/08/2023 |
06/30/2023 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 279 | $63.32 | $17.7k | | 06/30/2023 |
06/01/2023 | Cibus, Inc. | CLXT | Purchase | Class A Common Stock | 1000 | $31.50 | $31.5k | | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class B Common Stock | 1.4M | $0.00 | $0 | | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class B Common Stock | 20.9k | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class B Common Stock | 1.5M | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Cibus Common Units | 1.4M | $0.00 | $0 | | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Cibus Common Units | 20.9k | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Cibus Common Units | 1.5M | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 2.9k | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 118.9k | $0.00 | $0 | See footnote | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 5.4k | $0.00 | $0 | | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 9.6k | $0.00 | $0 | By spouse | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 168k | $0.00 | $0 | | 05/31/2023 |
05/31/2023 | Cibus, Inc. | CLXT | Grant | Class A Common Stock | 848.7k | $0.00 | $0 | | 05/31/2023 |
05/22/2023 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 1.8M | $32.82 | $57.4M | | 05/22/2023 |
05/09/2023 | Royalty Pharma plc | RPRX | Conversion | Class A Ordinary Shares | 300k | $0.00 | $0 | | 05/09/2023 |
05/09/2023 | Royalty Pharma plc | RPRX | Conversion | LP interests in RPI US Partners 2019, LP | 30k | $0.00 | $0 | | 05/09/2023 |
03/31/2023 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 313 | $54.15 | $16.9k | | 03/31/2023 |
12/30/2022 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 321 | $52.92 | $17k | | 12/30/2022 |
12/09/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 20k | $42.07 | $840.9k | | 12/09/2022 |
11/17/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 120k | $42.33 | $5.1M | | 11/17/2022 |
09/30/2022 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 365 | $46.53 | $17k | | 09/30/2022 |
09/15/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 52k | $42.21 | $2.2M | | 09/14/2022 |
09/14/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 48k | $42.41 | $2M | | 09/14/2022 |
08/09/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 45k | $43.73 | $2M | | 08/09/2022 |
06/30/2022 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 289 | $57.08 | $16.5k | | 06/30/2022 |
06/29/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 30k | $42.17 | $1.3M | | 06/29/2022 |
06/09/2022 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Stock Option (right to buy) | 16.8k | $55.48 | $929.7k | | 06/09/2022 |
05/20/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 123.7k | $39.28 | $4.9M | | 05/19/2022 |
05/19/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 26.3k | $40.09 | $1.1M | | 05/19/2022 |
03/31/2022 | Intra-Cellular Therapies, Inc. | ITCI | Grant | Common Stock | 257 | $61.19 | $15.7k | | 03/31/2022 |
03/29/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 60k | $38.59 | $2.3M | | 03/29/2022 |
03/21/2022 | Royalty Pharma plc | RPRX | Sale | Class A Ordinary Shares | 25.5k | $39.05 | $997.6k | By New Ventures Select | 03/17/2022 |
|
|